Skip to main content
NCBI home page
Occupational and Environmental Medicine logoLink to Occupational and Environmental Medicine
. 2002 Sep;59(9):608–612. doi: 10.1136/oem.59.9.608

Occupational exposure to cytotoxic drugs in two UK oncology wards

E Ziegler 1, H Mason 1, P Baxter 1
PMCID: PMC1740366  PMID: 12205233

Abstract

Aims: To investigate the potential exposure to cytotoxic drugs of staff on two oncology wards in a large district, UK hospital under normal working conditions.

Methods: Cytotoxic drug exposure was monitored in urine samples, surface wipes, and on disposable gloves by using a number of commonly used marker drugs, namely cyclophosphamide, ifosfamide, methotrexate, and the platino coordinated drugs. Questionnaire data on their work practices, potential exposure, use of protective personal equipment, and relevant training were collected from nursing, domestic, and clerical staff on two oncology wards.

Results: The majority of staff were female with a mean age of 31 years. Roughly half of the staff studied were specifically trained nurses with an average of 3.5 years experience of administering cytotoxic drugs. No cytotoxic drug preparation or reconstitution was carried out on the wards. Disposable gloves, plastic armlets and aprons, but not eye protection, were invariably worn where there was potential exposure to cytotoxics. No cytotoxic drug was detected in any of the staff's urine samples. Isolated disposable latex gloves from nurses administering drugs showed some contamination, as did some surfaces within the wards' sluice rooms, but not in the ward areas where the drugs were stored and checked prior to administration.

Conclusions: The risk management strategies in place, including use of personal protective equipment, staff training, and other organisational measures, have ensured that internal exposure is lower than the detection limits for the current biological monitoring methods. Levels of contamination appear significantly lower than earlier, non-UK published studies where different risk management strategies were in place and, in particular, ward staff may have been involved in some degree of cytotoxic drug reconstitution.

Full Text

The Full Text of this article is available as a PDF (110.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anwar W. A., Salama S. I., el Serafy M. M., Hemida S. A., Hafez A. S. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis. 1994 Jul;9(4):315–317. doi: 10.1093/mutage/9.4.315. [DOI] [PubMed] [Google Scholar]
  2. Baxter P. J. Research in occupational health. The UK National Health Service. J Soc Occup Med. 1991 Spring;41(1):7–9. doi: 10.1093/occmed/41.1.7. [DOI] [PubMed] [Google Scholar]
  3. Burgaz S., Karahalil B., Bayrak P., Taşkin L., Yavuzaslan F., Bökesoy I., Anzion R. B., Bos R. P., Platin N. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res. 1999 Feb 2;439(1):97–104. doi: 10.1016/s1383-5718(98)00180-6. [DOI] [PubMed] [Google Scholar]
  4. Ensslin A. S., Huber R., Pethran A., Römmelt H., Schierl R., Kulka U., Fruhmann G. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997;70(3):205–208. doi: 10.1007/s004200050208. [DOI] [PubMed] [Google Scholar]
  5. Ensslin A. S., Pethran A., Schierl R., Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994;65(5):339–342. doi: 10.1007/BF00405699. [DOI] [PubMed] [Google Scholar]
  6. Ensslin A. S., Stoll Y., Pethran A., Pfaller A., Römmelt H., Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994 Apr;51(4):229–233. doi: 10.1136/oem.51.4.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evelo C. T., Bos R. P., Peters J. G., Henderson P. T. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986;58(2):151–155. doi: 10.1007/BF00380766. [DOI] [PubMed] [Google Scholar]
  8. Fucic A., Jazbec A., Mijic A., Seso-Simic D., Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat Res. 1998 Aug 7;416(1-2):59–66. doi: 10.1016/s1383-5718(98)00084-9. [DOI] [PubMed] [Google Scholar]
  9. Gorodetsky R., Mou X., Vexler A., Kaufman B., Catane R., Loewenthal E. Noninvasive follow-up of platinum pharmacokinetics in the skin of patients on cisplatin chemotherapy. Cancer. 1993 Jul 15;72(2):446–454. doi: 10.1002/1097-0142(19930715)72:2<446::aid-cncr2820720221>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  10. Hansen J., Olsen J. H. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994 Feb;20(1):22–26. doi: 10.5271/sjweh.1433. [DOI] [PubMed] [Google Scholar]
  11. Hirst M., Tse S., Mills D. G., Levin L., White D. F. Occupational exposure to cyclophosphamide. Lancet. 1984 Jan 28;1(8370):186–188. doi: 10.1016/s0140-6736(84)92111-1. [DOI] [PubMed] [Google Scholar]
  12. Jardine I., Fenselau C., Appler M., Kan M. N., Brundrett R. B., Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 1978 Feb;38(2):408–415. [PubMed] [Google Scholar]
  13. McDevitt J. J., Lees P. S., McDiarmid M. A. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993 Jan;35(1):57–60. [PubMed] [Google Scholar]
  14. Minoia C., Turci R., Sottani C., Schiavi A., Perbellini L., Angeleri S., Draicchio F., Apostoli P. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom. 1998;12(20):1485–1493. doi: 10.1002/(SICI)1097-0231(19981030)12:20<1485::AID-RCM333>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  15. Nieweg R. M., de Boer M., Dubbleman R. C., Gall H. E., Hesselman G. M., Lenssen P. C., van Maanen L. W., Majoor P. W., Ouwerkerk J., Slegt J. H. Safe handling of antineoplastic drugs. Results of a survey. Cancer Nurs. 1994 Dec;17(6):501–511. [PubMed] [Google Scholar]
  16. Ota K., Oguma T., Shimamura K. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S. Anticancer Res. 1994 May-Jun;14(3B):1383–1387. [PubMed] [Google Scholar]
  17. Rogers B. Health hazards to personnel handling antineoplastic agents. Occup Med. 1987 Jul-Sep;2(3):513–524. [PubMed] [Google Scholar]
  18. Schierl R., Rohrer B., Hohnloser J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother Pharmacol. 1995;36(1):75–78. doi: 10.1007/BF00685736. [DOI] [PubMed] [Google Scholar]
  19. Schramel P., Wendler I., Lustig S. Capability of ICP-MS (pneumatic nebulization and ETV) for Pt-analysis in different matrices at ecologically relevant concentrations. Anal Bioanal Chem. 1995 Sep;353(2):115–118. doi: 10.1007/s0021653530115. [DOI] [PubMed] [Google Scholar]
  20. Seideman P., Beck O., Eksborg S., Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993 Apr;35(4):409–412. doi: 10.1111/j.1365-2125.1993.tb04158.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sessink P. J., Anzion R. B., Van den Broek P. H., Bos R. P. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992 Feb 21;14(1):16–22. doi: 10.1007/BF01989220. [DOI] [PubMed] [Google Scholar]
  22. Sessink P. J., Boer K. A., Scheefhals A. P., Anzion R. B., Bos R. P. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64(2):105–112. doi: 10.1007/BF00381477. [DOI] [PubMed] [Google Scholar]
  23. Sessink P. J., Friemèl N. S., Anzion R. B., Bos R. P. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994;65(6):401–403. doi: 10.1007/BF00383251. [DOI] [PubMed] [Google Scholar]
  24. Sessink P. J., Kroese E. D., van Kranen H. J., Bos R. P. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995;67(5):317–323. doi: 10.1007/BF00385647. [DOI] [PubMed] [Google Scholar]
  25. Sessink P. J., Van de Kerkhof M. C., Anzion R. B., Noordhoek J., Bos R. P. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994 May-Jun;49(3):165–169. doi: 10.1080/00039896.1994.9940377. [DOI] [PubMed] [Google Scholar]
  26. Skov T., Maarup B., Olsen J., Rørth M., Winthereik H., Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992 Dec;49(12):855–861. doi: 10.1136/oem.49.12.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sorsa M., Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res. 1996 Aug 17;355(1-2):253–261. doi: 10.1016/0027-5107(96)00031-0. [DOI] [PubMed] [Google Scholar]
  28. Valanis B., Vollmer W. M., Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999 Aug;41(8):632–638. doi: 10.1097/00043764-199908000-00004. [DOI] [PubMed] [Google Scholar]
  29. Venitt S., Crofton-Sleigh C., Hunt J., Speechley V., Briggs K. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption. Lancet. 1984 Jan 14;1(8368):74–77. doi: 10.1016/s0140-6736(84)90005-9. [DOI] [PubMed] [Google Scholar]

Articles from Occupational and Environmental Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES